earnings, page-4

SB those imclone earnings are the result of license deals and drug sales . Oncologists are including the drug in their treatments because it has some response and may be of help . I think they are buying it in spite of Martha and Sam , and will till something better comes along . There are lots of other examples . OSIP s new drug Tarceva has pushed its shares to 91 USD on increased survival times of a few monthe , Teliks Telcyta is better and its shares are 26 USD . Dendreons Provenge in developement with a share price of around 14USD and even Celgene , which has just had their phase 3 trials shut down as a failure and intends to pursue other cancers with their drug thalomid(thalidomide) has a share price of 51 USD .
If you research these companies lead compounds , you will see none seem to have the potential of Solbecs SBP002 . It has surely got to be a total bargain at this current price .